AI-Driven Treatment Strategy vs Pola-R-CHP in Untreated LBCL
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Clinical Trials Related to Zanubrutinib
Related studies linked through entity extraction aliases.
A Study of Rocbrutinib Versus Investigator's Choice of BTK Inhibitors in Patients With Relapsed or Refractory Mantle Cell Lymphoma
- Status
- RECRUITING
- Phase
- PHASE3
Sonrotoclax Plus Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma Planned for Standard of Care CAR-T Cell Therapy
- Status
- RECRUITING
- Phase
- PHASE2
Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE3
Zanubrutinib and Acalabrutinib Use and Risk of Atrial Fibrillation in Patients With Chronic B-cell Malignancies
- Status
- NOT_YET_RECRUITING
- Phase
- N/A
A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia
- Status
- RECRUITING
- Phase
- PHASE3
A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell Malignancies
- Status
- RECRUITING
- Phase
- PHASE2
Zanubrutinib Combined With Rituximab in the Treatment of Secondary HLH in B-cell Lymphoma
- Status
- RECRUITING
- Phase
- PHASE4
Obinutuzumab, Zanubrutinib, and Lenalidomide in First-line Treatment of Mantle Cell Lymphoma
- Status
- RECRUITING
- Phase
- PHASE2
Zanubrutinib Combined With Rituximab in the Treatment for Patients With Marginal Zone Lymphoma
- Status
- RECRUITING
- Phase
- N/A
A Study to Evaluate the Efficacy and Safety of Zanubrutinib in Chinese Adults With Treatment-Naive Waldenström Macroglobulinemia
- Status
- RECRUITING
- Phase
- PHASE4
A Study to Investigate the Relative Bioavailability and Food Effect of a Fixed-Dose Combination Tablet Containing Zanubrutinib and Sonrotoclax (BG-71332) in Healthy Adults
- Status
- COMPLETED
- Phase
- PHASE1
Mosunetuzumab for CLL MRD Clearance
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Glofitamab, Polatuzumab Vedotin and Zanubrutinib in First-line Elderly DLBCL
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Phase II Trial of Zanubrutinib, Obinutuzumab, Bendamustine (ZGB) as First-Line Therapy for Chronic Lymphocytic Leukemia: A Single-Center Study
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
ZR-MTX for PIOL Phase II Trial
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Zanubrutinib Combined With BR in the First-line Treatment of Waldenström's Macroglobulinemia
- Status
- NOT_YET_RECRUITING
- Phase
- NA
Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
- Status
- RECRUITING
- Phase
- PHASE1
BRAZAN: A Randomized Phase 2 Study of Bendamustine, Rituximab, Cytarabine (AraC) Induction With Zanubrutinib (BRAZAN) Followed by Zanubrutinib/Rituximab +/- Sonrotoclax Maintenance in Treatment-Naïve Mantle Cell Lymphoma
- Status
- RECRUITING
- Phase
- PHASE2
Zanubrutinib, Obinutuzumab, and Sonrotoclax in Previously Untreated Patients With CLL or SLL
- Status
- RECRUITING
- Phase
- PHASE2